We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+7.47%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$12.3B
AUM Growth
+$1.06B
Cap. Flow
+$761M
Cap. Flow %
6.18%
Top 10 Hldgs %
58.32%
Holding
100
New
18
Increased
36
Reduced
17
Closed
19

Top Buys

Rank Stock Value
1
AET
Aetna Inc
AET
+$896M
2
COL
Rockwell Collins
COL
+$339M
3
MON
Monsanto Co
MON
+$161M
4
ELV icon
Elevance Health
ELV
+$131M
5
CHTR icon
Charter Communications
CHTR
+$92.5M

Top Sells

Rank Stock Value
1
BCR
CR Bard Inc.
BCR
+$508M
2
TWX
Time Warner Inc
TWX
+$393M
3
HDS
HD Supply Holdings, Inc.
HDS
+$196M
4
KITE
Kite Pharma, Inc.
KITE
+$175M
5
ALR
Alere Inc
ALR
+$138M

Sector Composition

Rank Sector Weight
1 Technology 22.48%
2 Healthcare 13.94%
3 Communication Services 13.94%
4 Financials 11.79%
5 Industrials 6.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LKFT
51
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.78B
$27.2M 0.22%
290,000
+53,784
+23% +$5.09M
NVCR icon
52
NovoCure
NVCR
$1.73B
$23.5M 0.19%
+1,165,000
New +$22.4M
NTLA icon
53
Intellia Therapeutics
NTLA
$1.49B
$21.9M 0.18%
+1,140,000
New +$26.3M
CRSP icon
54
CRISPR Therapeutics
CRSP
$4.73B
$20.2M 0.16%
+858,602
New +$16.3M
HRG
55
DELISTED
HRG Group, Inc.
HRG
$19.4M 0.16%
1,142,000
+157,000
+16% +$2.54M
SPB icon
56
Spectrum Brands
SPB
$2.04B
$19.1M 0.16%
170,000
+23,000
+16% +$2.51M
LUMN icon
57
PUT
Lumen
LUMN
$6.57B
$19.1M 0.16%
1,144,000
– –
PTGX icon
58
Protagonist Therapeutics
PTGX
$8.79B
$18.7M 0.15%
+900,000
New +$16M
EDIT icon
59
Editas Medicine
EDIT
$396M
$15.8M 0.13%
+515,000
New +$13M
CAVM
60
DELISTED
Cavium, Inc.
CAVM
$15.1M 0.12%
+180,000
New +$13.9M
IOVA icon
61
Iovance Biotherapeutics
IOVA
$1.82B
$14.9M 0.12%
1,866,900
+1,016,900
+120% +$8.16M
GBT
62
DELISTED
Global Blood Therapeutics, Inc.
GBT
$13.4M 0.11%
+340,000
New +$12.7M
HAIN icon
63
Hain Celestial
HAIN
$45M
$12.3M 0.1%
+290,000
New +$11.5M
AKBA icon
64
Akebia Therapeutics
AKBA
$354M
$12.3M 0.1%
825,000
+95,000
+13% +$1.58M
ASMB icon
65
Assembly Biosciences
ASMB
$498M
$11.3M 0.09%
+20,833
New +$9.43M
VYGR icon
66
Voyager Therapeutics
VYGR
$183M
$10.9M 0.09%
654,812
+487,147
+291% +$8.35M
CBAY
67
DELISTED
Cymabay Therapeutics
CBAY
$10.1M 0.08%
+1,100,000
New +$9.4M
BOLD
68
DELISTED
Audentes Therapeutics, Inc
BOLD
$9.99M 0.08%
+319,662
New +$8.78M
ZEAL
69
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
$8.84M 0.07%
650,000
– –
WGL
70
DELISTED
Wgl Holdings
WGL
$8.58M 0.07%
100,000
-20,000
-17% -$1.71M
XPO icon
71
XPO
XPO
$23.6B
$8.24M 0.07%
+260,225
New +$6.65M
MRNS
72
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$7.3M 0.06%
223,750
-68,750
-24% -$1.85M
BG icon
73
Bunge Global
BG
$20.4B
$7.04M 0.06%
+105,000
New +$7.14M
NCNA
74
NuCana
NCNA
$5.49M
$4.04M 0.03%
80
– –
TROX icon
75
Tronox
TROX
$932M
$3.88M 0.03%
+189,375
New +$4.62M
1 2
3
4

Similar funds

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farallon Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, Farallon Capital Management held 100 positions worth $12.3B, up 9.4% from $11.3B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Farallon Capital Management deployed $761M of net new capital in Q4 2017, opening 18 new positions and adding to 36 existing holdings. Its largest new stake was Aetna Inc: 5,215,000 shares worth $941M.

By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 24% a quarter earlier, followed by Healthcare and Communication Services.

On the sell side, the largest reduction was Time Warner Inc, an estimated $393M trimmed.

  • Farallon Capital Management's largest Q4 2017 buy was Aetna Inc: 5,215,000 shares worth $941M.
  • Farallon Capital Management added most to Monsanto Co in Q4 2017, an estimated $161M increase.
  • Farallon Capital Management's biggest Q4 2017 reduction was Time Warner Inc, cutting an estimated $393M.
  • Farallon Capital Management fully exited CR Bard Inc. in Q4 2017, selling an estimated $508M.
  • Farallon Capital Management's ten largest holdings make up 58% of its $12.3B portfolio in Q4 2017.
  • Farallon Capital Management opened 18 new positions and closed 19 in Q4 2017.
  • Farallon Capital Management's portfolio value rose 9.4% quarter-over-quarter to $12.3B.

Based on Farallon Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.